Medical Product Industry Ties to Patient Advocacy Organizations’ Executive Leadership-Reference-Cited by-同舟云学术

Medical Product Industry Ties to Patient Advocacy Organizations’ Executive Leadership

Published:2023-10-01 Issue:10 Volume:183 Page:1164
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Bhat Shamik¹,Ross Joseph S.²³⁴⁵,Ramachandran Reshma²³

Affiliation:

1. Yale School of Medicine, New Haven, Connecticut

2. Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

3. Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, Connecticut

4. Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut

5. Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, Connecticut

Abstract

This cross-sectional study examines the ties between pharmaceutical and medical device industries and the executive leadership of the 50 highest-revenue US-based patient advocacy organizations.

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2808240/jamainternal_bhat_2023_ld_230021_1695921508.18644.pdf

Reference6 articles.

1. Financial relationships between patient and consumer representatives and the health industry: a systematic review.;Khabsa;Health Expect,2020

2. Conflicts of interest for patient-advocacy organizations.;McCoy;N Engl J Med,2017

3. Industry support of patient advocacy organizations: the case for an extension of the sunshine act provisions of the Affordable Care Act.;McCoy;Am J Public Health,2018

4. Toward a healthier patient voice: more independence, less industry funding.;Moynihan;JAMA Intern Med,2017

5. Kopp? E, Lupkin? S, Lucas? E. Patient advocacy groups take in millions from drugmakers. Is there a payback? Kaiser Health News. Accessed April 28, 2022. https://khn.org/news/patient-advocacy-groups-take-in-millions-from-drugmakers-is-there-a-payback/